Abstract
Since the identification of the hepatitis C virus, great strides have been made in the development of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, interferon-α (IFN-α) was a natural choice for treatment. Whereas treatment with IFN-α alone achieved only modest success, the addition of the broad-spectrum antiviral agent ribavirin greatly improved responses. However, half of the infected individuals with chronic disease do not achieve sustained clearance of hepatitis C virus. To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hoofnagle, J. H. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. New Engl. J. Med. 315, 1575–1578 (1986).
Lau, D. T. et al. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28, 1121–1127 (1998).
Di Bisceglie, A. M. & Hoofnagle, J. H. Optimal therapy of hepatitis C. Hepatology 36, S121–S127 (2002).
McHutchison, J. G. & Poynard, T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis. 19 (Suppl. 1), 57–65 (1999).
Glue, P. et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 68, 556–567 (2000).
Zeuzem, S. et al. PEGinterferon α-2a in patients with chronic hepatitis C. New Engl. J. Med. 343, 1666–1672 (2000).
Heathcote, E. J. et al. PEGinterferon α-2a in patients with chronic hepatitis C and cirrhosis. New Engl. J. Med. 343, 1673–1680 (2000).
Lindsay, K. L. et al. A randomized, double-blind trial comparing PEGylated interferon alfa-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395–403 (2001).
Manns, M. P. et al. PEGinterferon α-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958–965 (2001).
Fried, M. W. et al. PEGinterferon α-2a plus ribavirin for chronic hepatitis C virus infection. New Engl. J. Med. 347, 975–982 (2002).
Hadziyannis, S. J. et al. PEGinterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346–355 (2004).
Strader, D. B. Understudied populations with hepatitis C. Hepatology 36, S226–S236 (2002).
Marcellin, P. et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 127, 875–881 (1997).
Shiffman, M. L. Retreatment of patients with chronic hepatitis C. Hepatology 36, S128–S134 (2002).
Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103–107 (1998).
Layden, J. E. & Layden, T. J. Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology 35, 967–970 (2002).
Lau, J. Y. et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann. Intern. Med. 124, 868–876 (1996).
Muir, A. J., Bornstein, J. D. & Killenberg, P. G. PEGinterferon α-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New Engl. J. Med. 350, 2265–2271 (2004).
Jaeckel, E. et al. Treatment of acute hepatitis C with interferon α-2b. New Engl. J. Med. 345, 1452–1457 (2001).
Santantonio, T. et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol. 42, 329–333 (2005).
Bekisz, J., Schmeisser, H., Hernandez, J., Goldman, N. D. & Zoon, K. C. Human interferons alpha, beta and omega. Growth Factors 22, 243–251 (2004).
Sen, G. C. Viruses and interferons. Annu. Rev. Microbiol. 55, 255–281 (2001).
Robek, M. D., Boyd, B. S. & Chisari, F. V. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79, 3851–3854 (2005).
Frese, M. et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35, 694–703 (2002).
Soza, A. et al. Pilot study of interferon gamma for chronic hepatitis C. J. Hepatol. 43, 67–71 (2005).
Gilmour, K. C. & Reich, N. C. Signal transduction and activation of gene transcription by interferons. Gene Expr. 5, 1–18 (1995).
Gale, M. Jr Effector genes of interferon action against hepatitis C virus. Hepatology 37, 975–978 (2003).
de Veer, M. J. et al. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukocyte Biol. 69, 912–920 (2001).
Lanford, R. E. et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J. Virol. 77, 1092–1104 (2003).
Sumpter, R. Jr et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79, 2689–2699 (2005).
Blight, K. J., Kolykhalov, A. A. & Rice, C. M. Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972–1974 (2000).
Guo, J. T., Bichko, V. V. & Seeger, C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75, 8516–8523 (2001).
Abe, K. et al. cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells. Virus Res. 107, 73–81 (2005).
Zhu, H. et al. Gene expression associated with interferon α antiviral activity in an HCV replicon cell line. Hepatology 37, 1180–1188 (2003).
Guo, J. T., Sohn, J. A., Zhu, Q. & Seeger, C. Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology 325, 71–81 (2004).
Bigger, C. B. et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 78, 13779–13792 (2004).
Bigger, C. B., Brasky, K. M. & Lanford, R. E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75, 7059–7066 (2001).
Su, A. I. et al. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl Acad. Sci. USA 99, 15669–15674 (2002).
Ji, X. et al. Interferon α regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37, 610–621 (2003).
Chen, L. et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437–1444 (2005).
Enomoto, N. et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New Engl. J. Med. 334, 77–81 (1996).
Herion, D. & Hoofnagle, J. H. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology 25, 769–771 (1997).
Gale, M. J. Jr et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217–227 (1997).
Gale, M. Jr et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18, 5208–5218 (1998).
Wang, C. et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 77, 3898–3912 (2003).
Khabar, K. S. et al. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J. Exp. Med. 186, 1077–1085 (1997).
Polyak, S. J. et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75, 6095–6106 (2001).
Girard, S. et al. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 295, 272–283 (2002).
Polyak, S. J., Khabar, K. S., Rezeiq, M. & Gretch, D. R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75, 6209–6211 (2001).
Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N. & Lai, M. M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107–110 (1999).
Pavio, N., Taylor, D. R. & Lai, M. M. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J. Virol. 76, 1265–1272 (2002).
Foy, E. et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145–1148 (2003).
Foy, E. et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA 102, 2986–2991 (2005).
Frese, M., Pietschmann, T., Moradpour, D., Haller, O. & Bartenschlager, R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 82, 723–733 (2001).
Blindenbacher, A. et al. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 124, 1465–1475 (2003).
Basu, A., Meyer, K., Ray, R. B. & Ray, R. Hepatitis C virus core protein modulates the interferon-induced transacting factors of JAK/STAT signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 288, 379–390 (2001).
Heim, M. H., Moradpour, D. & Blum, H. E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J. Virol. 73, 8469–8575 (1999).
Honda, M., Shimazaki, T. & Kaneko, S. La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation. Gastroenterology 128, 449–462 (2005).
Katze, M. G., He, Y. & Gale, M. Jr. Viruses and interferon: a fight for supremacy. Nature Rev. Immunol. 2, 675–687 (2002).
Taylor, D. R. Hepatitis C virus: evasion of the interferon-induced antiviral response. J. Mol. Med. 78, 182–190 (2000).
Tilg, H. New insights into the mechanisms of interferon α: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112, 1017–1021 (1997).
Lechner, F. et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191, 1499–1512 (2000).
Kamal, S. M. et al. PEGylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39, 1721–1731 (2004).
Rahman, F. et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 40, 87–97 (2004).
Kamal, S. M., Fehr, J., Roesler, B., Peters, T. & Rasenack, J. W. PEGinterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123, 1070–1083 (2002).
Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev. Immunol. 5, 215–229 (2005).
Thomson, M. et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J. Virol. 77, 862–870 (2003).
Di Bisceglie, A. M. et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123, 897–903 (1995).
Hoofnagle, J. H., Lau, D., Conjeevaram, H., Kleiner, D. & Di Bisceglie, A. M. Prolonged therapy of chronic hepatitis C with ribavirin. J. Viral Hepat. 3, 247–252 (1996).
Pawlotsky, J. M. et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126, 703–714 (2004).
Lindahl, K., Stahle, L., Bruchfeld, A. & Schvarcz, R. High-dose ribavirin in combination with standard dose PEGinterferon for treatment of patients with chronic hepatitis C. Hepatology 41, 275–279 (2005).
Lau, J. Y., Tam, R. C., Liang, T. J. & Hong, Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35, 1002–1009 (2002).
Maag, D., Castro, C., Hong, Z. & Cameron, C. E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276, 46094–46098 (2001).
Crotty, S., Cameron, C. E. & Andino, R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl Acad. Sci. USA 98, 6895–6900 (2001).
Crotty, S. et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Med. 6, 1375–1379 (2000).
Zhou, S., Liu, R., Baroudy, B. M., Malcolm, B. A. & Reyes, G. R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310, 333–342 (2003).
Contreras, A. M. et al. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76, 8505–8517 (2002).
Lanford, R. E. et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75, 8074–8081 (2001).
Young, K. C. et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38, 869–878 (2003).
Lutchman, G. A. et al. Mutation rate of hepatitis C virus in patients during ribavirin monotherapy. Hepatology 41, 385A (2004).
Layden-Almer, J. E., Ribeiro, R. M., Wiley, T., Perelson, A. S. & Layden, T. J. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37, 1343–1350 (2003).
Dixit, N. M., Layden-Almer, J. E., Layden, T. J. & Perelson, A. S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432, 922–924 (2004).
Tam, R. C. et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J. Hepatol. 30, 376–382 (1999).
Cramp, M. E. et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118, 346–355 (2000).
Zhang, Y. et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Virol. 77, 5933–5947 (2003).
Fiedler, M. A., Wernke-Dollries, K. & Stark, J. M. Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells. J. Virol. 70, 9079–9082 (1996).
Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 11, 791–796 (2005).
Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294–9299 (2005).
Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623–626 (2005).
Reesink, H. W. et al. Initial results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Gastroenterology 128, 527A (2005).
Rodriguez-Torres, M. et al. Valopicitabine (nm283) alone and in combination with PEG-interferon in patients with genotype 1 chronic hepatitis C: preliminary results from an ongoing phase 1i, multicenter study. Gastroenterology 128, 695A (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Author Information Reprints and permissions information is available at npg.nature.com/reprintsandpermissions.
Rights and permissions
About this article
Cite this article
Feld, J., Hoofnagle, J. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967–972 (2005). https://doi.org/10.1038/nature04082
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature04082
This article is cited by
-
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
BMC Gastroenterology (2022)
-
Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer
Nature Communications (2021)
-
TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response
Inflammation (2019)
-
Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model
Scientific Reports (2018)
-
Identification of Inhibitory Compounds Against Singapore Grouper Iridovirus Infection by Cell Viability-Based Screening Assay and Droplet Digital PCR
Marine Biotechnology (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.